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The intent of this review is to update the science of emerging cardiometabolic risk factors that were listed in the
National Cholesterol Education Program (NCEP) Adult Treatment Panel-III (ATP-III) report of 2001 (updated in 2004). At
the time these guidelines were published, the evidence was felt to be insufficient to recommend these risk factors
for routine screening of cardiovascular disease risk. However, the panel felt that prudent use of these biomarkers for
patients at intermediate risk of a major cardiovascular event over the subsequent 10 years might help identify
patients who needed more aggressive low density lipoprotein (LDL) or non-high density lipoprotein (HDL)
cholesterol lowering therapy. While a number of other emerging risk factors have been identified, this review will
be limited to assessing the data and recommendations for the use of apolipoprotein B, lipoprotein (a), homocysteine,
pro-thrombotic factors, inflammatory factors, impaired glucose metabolism, and measures of subclinical atherosclerotic
cardiovascular disease for further cardiovascular disease risk stratification.
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It has been long known that certain factors and conditions
are associated with increased risk for cardiovascular
disease (CVD) and when present warrant more aggres-
sive management. These major risk factors include age,
sex, family history, hypertension, diabetes, cholesterol
and smoking, with elevated high density lipoprotein
(HDL) cholesterol as being protective or a ‘negative’ risk
factor. These major risk factors were the basis for the
recommendations set forth by the National Cholesterol
Education Program (NCEP) Adult Treatment Panel-III
(ATP-III) report of 2001 [1] (updated in 2004) [2]. A num-
ber of other cardiometabolic risk factors, so called ‘emerging
risk factors,’ have also been identified and reviewed [3,4].
These risk factors include, but are not limited to, obesity,
metabolic syndrome, hypertriglyceridemia, apolipoprotein
B, lipoprotein (a), homocysteine, pro-thrombotic factors,
pro-inflammatory factors as well as measures of subclin-
ical atherosclerotic cardiovascular disease (ASCVD). At
the time the ATP-III report was published the evidence
was felt to be insufficient to recommend these risk factors* Correspondence: robert.eckel@ucdenver.edu
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2014for routine screening of CVD. However, the ATP-III panel
felt that prudent use of these biomarkers for patients
at intermediate risk of a major CVD event over the
subsequent 10 years might help identify patients who
needed more aggressive low density lipoprotein (LDL)
or non-HDL cholesterol lowering therapy.
The more recent 2013 American College of Cardiology/
American Heart Association (ACC/AHA) Guideline on the
Assessment of Cardiovascular Risk has also made recom-
mendations on the use of some of these emerging risk fac-
tors, including markers of inflammation and subclinical
ASCVD [5]. The European (European Guidelines on
Cardiovascular Disease Prevention in Clinical Practice) [6]
and Canadian (2012 Update of the Canadian Cardiovascular
Society Guidelines for the Diagnosis and Treatment of
Dyslipidemia for the Prevention of Cardiovascular Disease
in the Adult) [7] guidelines have also been recently up-
dated, both reviewing and making recommendations
on a number of these emerging cardiometabolic risk
factors. These recommendations have been summarized
in Table 1 illustrating the lack of consensus regarding
these risk factors.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 European, Canadian and ACC/AHA guidelines on the use of emerging risk factors
Emerging risk factor European [6] Canadian [7] ACC/AHA [5]
Apo B No added value; may be a more accurate
assessment of CVD risk versus LDL-C in
patients with hypertriglyceridemia
≥120 mg/dL as an alternative
marker for intermediate risk
patients with LDL-C <3.5 mmol/L
Screening not recommended
Lipoprotein (a) Screening not recommended Consider for intermediate risk
patients. Levels >30 mg/dL
considered higher CVD risk
Screening not recommended
Homocysteine May be used in persons at moderate
CVD risk.
Screening not recommended Screening not recommended
Pro-thrombotic factors Fibrinogen may be used in persons at
moderate CVD risk.
Screening not recommended Screening not recommended
Pro-inflammatory factors hsCRP may be used in persons at
moderate CVD risk.
Screening not recommended Consider screening with hsCRP
for intermediate risk patients and
consider statin therapy for
patients with levels ≥2 mg/dL.
Impaired fasting glucose Screening not recommended Recommended for all for risk
stratification and diagnosis of
diabetes
Screening not recommended
Subclinical atherosclerosis Consider statin therapy for asymptomatic
patients at moderate risk with carotid
plaque ≥0.5 mm of IMT or IMT ≥1.5 mm.
Recommendations based on CCS are
vague but a high CCS is a high CVD risk
and a statin should be prescribed.
For intermediate risk patients
consider statin therapy for
patients with carotid plaque or
CIMT >75th %tile for age and
gender; and for a CCS >100
Agatston units.
Consider statin therapy for patients
with a calculated 10 year CVD risk
between 5.0% to 7.5% or even
<5.0% with a CCS ≥300 Agatston
units or ≥75th %tile for age, gender
and ethnicity.
ACC/AHA, American College of Cardiology/American Heart Association; Apo-B, apolipoprotein B; CCS,; CIMT, carotid intima-media thickness; CVD, cardiovascular
disease; hsCRP, high sensitivity C-reactive protein; IMT, intima media thickness; LDL-C, low density lipoprotein cholesterol.
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Apolipoprotein B
Apolipoprotein B (apo B) is the major protein on pro-
atherogenic lipoproteins (apo B-containing lipoproteins).
There is one molecule of apo B in very low density
lipoprotein (VLDL), VLDL remnants, low density lipo-
protein (LDL) and lipoprotein (a) particles establishing
levels of apo B as a reference to pro-atherogenic particles.
Levels of apo B correlate well with levels of non-HDL-C,
r >0.80 [8-10]. Because levels of apo B represent all pro-
atherogenic particles, the replacement of fasting plasma
lipids with apo B to assess CVD risk has been supported
by many [11,12]. An additional advantage of measuring
apo B as compared to lipids is that fasting may not be
necessary because changes in apo B100 after eating are
minimally different than those measured in the fed state
[13,14]. However, although more recent analyses have
found that non-HDL-C and apo B perform better than
LDL-C in CVD risk prediction, both on- and off-treatment,
as well as in subclinical CVD risk prediction [15],
the current dogma from the Emerging Risk Factors
Collaboration remains that apo B is similar to LDL-C and
non-HDL-C in the prediction of CVD [16]. Moreover,
when compared to total cholesterol/HDL cholesterol in
primary [17] and secondary [18] CVD prevention trials,
apo B was similar or weaker than the ratio, respectively, in
predicting CVD events.
An important situation in which apo B may have
value is in patients in whom LDL-C levels are low, forexample, <100 mg/dL, and plasma triglycerides (TG)
are elevated. Although levels of non-HDL-C may be
helpful, apo B may provide additional information about
the number of pro-atherogenic particles. It is important to
realize that for any given level of non-HDL-C the 95th per-
centage confidence intervals for apo B puts the apo B level
up to two-fold different [19] and this may be especially
important in the assessment and treatment of patients
with hypertriglyceridemia. Because LDL-C is low, a much
greater percentage of apo B is from apo B-containing par-
ticles other than LDL such as VLDL or IDL, and with a
potential two-fold difference in apo B at any given level of
LDL-C (<100 mg/dL), the level of apo B could be low at
65 mg/dL or high at 130 mg/dL; and thus provide mark-
edly different levels of CVD risk. In subjects selected from
2,023 consecutive patients attending the Lipid Clinic at
the Laval University Centre, 270 had mild hypertriglyc-
eridemia and normal levels of apo B, 163 moderate
hypertriglyceridemia and normal apo B, 458 mild
hypertriglyceridemia with elevations in apo B, and 295
moderate hypertriglyceridemia with elevations in apo
B [20]. Irrespective of levels of plasma apo B, patients
with mild versus moderate hypertriglyceridemia had
lower ratios of VLDL apo B/plasma apo B, a discrepancy
that may be important to the CVD risk. In fact, in the
Quebec Cardiovascular Study the relative risk for CVD
based on apo B in patients with hypertriglyceridemia has
been well documented [21]. Presently, both the Canadian
Guidelines and the American College of Cardiology
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established goals for apo B. The Canadian Guidelines
have established apo B goals of <80 mg/dL and <100
mg/dL for patients with CVD or at higher risk versus
lower CVD risk [22]. The ACC/ADA have set goals of
apo B at <80 mg/dL for patients with CVD or diabetes
and one risk factor and <90 mg/dL for patients with two
or more risk factors or with diabetes [23].
Lipoprotein (a)
Lipoprotein (a) is an apo B lipoprotein that includes
apolipoprotein (a) covalently bound to apo B. Plasma
concentrations of lipoprotein (a) are conferred mostly by
genetics that relate primarily to the size of the apo (a)
protein. The size of the isoform is dependent on a variable
number of kringle IV repeats in the lipoprotein (a) gene
[24] and a smaller number of repeats predict a higher con-
centration of lipoprotein (a) [25]. Lipoprotein (a) concentra-
tions can vary between undetectable to >200 mg/dL with a
two to three fold higher level seen in populations of African
descent. Plasma levels >30 mg/dL confer increased athero-
sclerotic risk [26]. The atherogenicity relates to multiple
features of the particle including the inability of the particle
to be cleared by the LDL receptor, anti-fibrinolytic proper-
ties due to the structural homology to plasminogen and
competition with plasminogen for its binding site, and
the particle carrying more atherogenic pro-inflammatory
oxidized phospholipids [27].
The relationship between lipoprotein (a) and CVD has
been well established. By 2000, there were more than 15
population-based prospective studies that reported on
higher levels of lipoprotein (a) and CHD risk, with most
reporting positive associations. In 2006, a study of 27,736
healthy women, of whom 12,075 indicated active hor-
mone replacement therapy at study initiation and 15,661
did not, demonstrated that women not taking female
hormones had a hazard ratio of future CVD events of
1.8 (highest lipoprotein (a) quintile versus lowest quintile,
P <0.0001) after multifactorial risk factor adjustment
[28]. For a number of years it was believed that levels >30
mg/dL were predictive of CHD events; however, more re-
cently, a gradient relationship between higher levels of lipo-
protein (a) and CVD has been evidenced. In the Reykjavik
Study (n = 18,569), levels of lipoprotein (a) were measured
at baseline from 2,047 patients with a non-fatal or fatal
myocardial infarction (MI) versus 3,921 control partic-
ipants. In addition to examining within-person fluctua-
tions, paired samples were assessed at an interval of 12
years in 372 subjects [29]. The odds ratio for CHD, un-
altered after adjustment for established risk factors was
1.60 in a comparison of extreme thirds of baseline lipo-
protein (a) concentrations. Moreover, odds ratios in-
creased in parallel with increasing levels of lipoprotein
(a). In the Copenhagen Heart Study, the association oflipoprotein (a) levels with CHD was also continuous
[30]. Risk rates for CHD of 1.16 and 1.13 were found
after lipoprotein (a) data were adjusted for age and sex
only and for lipids and other CVD risk factors, respectively,
when the top and bottom lipoprotein (a) tertiles were com-
pared. In AIM-HIGH (Atherothrombosis Intervention in
Metabolic Syndrome with Low HDL/High Triglyceride and
Impact on Global Health Outcomes) study, the baseline
and on-study lipoprotein (a) levels were predictive of CVD
events in the simvastatin plus placebo (baseline HR: 1.24,
P = 0.002) as well as in the on-extended release niacin
group (HR: 1.21, P = 0.017) [31]. In AIM-HIGH there was
a gradient CVD risk across quartiles of lipoprotein (a).
Finally, in Jupiter, baseline levels of lipoprotein (a) were not
only associated with additional CVD risk, among Caucasian
participants residual risk in statin-treated patients was
a determinant of residual risk (adjusted HR 1.27, 95%
confidence interval (CI) 1.01to 1.59; P = 0.04 [32].
Presently, no data exist to confirm that lowering lipo-
protein (a) reduces CVD risk; however, lipoprotein (a)
can be reduced by niacin, mipomersen, LDL apheresis,
cholesteryl ester transfer protein inhibitors, and estro-
gens [33]. Of interest, estrogens may confer benefit on
CVD events in post-menopausal women with the high-
est quintile of lipoprotein (a) [28]. A major problem with
interpretation of any studies using these medications is
that variably other lipoproteins are also altered favorably.
The anti-sense oligonucleotide from ISIS [34] may be
necessary before the independent effect of lipoprotein
(a) lowering is realized.
Homocysteine
Hyperhomocysteinemia can be as a result of deficiencies
of vitamin B6, folic acid or vitamin B12 or due to a rare
genetic enzyme defect. Hyperhomocysteinemia was first
associated with CVD risk as it relates to the rare auto-
somal recessive disorder, homocystinuria. Individuals
with homocystinuria have markedly elevated levels of
plasma homocysteine and have a very high risk of CVD
if untreated [35]. While the mechanisms are not clearly
elucidated, it appears that homocysteinemia is associated
with endothelial dysfunction and increased thrombosis
[36]. Furthermore, observational studies, both retrospect-
ive and prospective, have shown that even moderate eleva-
tions in homocysteine, even within the normal range, are
also associated with a higher risk of CVD [37,38]. A num-
ber of clinical trials have since been published examining
the effects of folic acid/B vitamin supplementation on pre-
venting CVD events [39-45]. These studies have been
done in individuals of moderate to very high risk of CVD
events and, while homocysteine levels are reduced with
folic acid/B vitamin supplementation, none of these stud-
ies has shown a benefit in clinical CVD outcomes. Clarke
and colleagues recently published a meta-analysis of these
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a total of 37,485 individuals and found that lowering
homocysteine levels by about 25% for a mean of five years
was not associated with significant beneficial effects on
CVD events. Specifically, no benefit was seen in major
CVD events (HR 1.01, CI 0.97 to 1.05), major coronary
events (HR 1.03, CI 0.97 to 1.10), stroke (HR 0.96, CI 0.87
to 1.06), or all-cause mortality (HR 1.00, CI 0.85 to 1.18)
[46]. The available evidence, therefore, does not support
the routine use of folic acid/B vitamin supplementation to
prevent cardiovascular disease or improve overall survival,
and as such there are no official recommendations for
routine testing for homocysteine.
Pro-thrombotic factors
Thrombosis is a critical process in the pathophysiology
associated with acute CVD events such as acute coronary
syndromes [47-49]. An unstable atherosclerotic plaque
may be prone to disruption leading to platelet aggregation
and acute thrombosis. Platelet activation has also been
shown to play an important role in driving atherosclerosis
progression as a mediator of endothelial function and in-
flammatory responses [48]. Furthermore, there is strong evi-
dence supporting the benefits of antiplatelet agents, such as
aspirin, in the primary and secondary therapy of CVD [50].
A recent meta-analysis found that aspirin therapy in primary
prevention trials was associated with a 12% reduction in ser-
ious CVD events but no effect on stroke or vascular mortal-
ity. In secondary prevention, aspirin was associated with a
more robust 18% reduction in serious CVD events [51].
Men appear to receive more benefit from aspirin in primary
prevention of CHD events while women appear to receive
more benefit in primary prevention of ischemic strokes [51].
It is less clear, however, whether biomarkers associated
with thrombosis and platelet aggregation are helpful in
clinical practice. Fibrinogen is a major coagulation protein
that plays a key role in blood viscosity and platelet aggre-
gation, and in a meta-analysis of prospective observational
studies a moderately strong association has been found
between fibrinogen levels and the risk of CVD [52,53].
However, because of analytical/assay concerns and uncer-
tainty in treatment strategies, the measurement of fibrino-
gen in clinical practice is not currently recommended [54].
Circulating tissue plasminogen activator (t-PA) antigen,
total plasminogen inhibitor-1 (tPAI-1), D-dimer, and von
Willebrand factor have also been found to be associated
with increased CVD risk, but more studies are needed to
assess their clinical applicability [55-57]. Furthermore, there
are no known related therapeutic interventions that are
available or proven successful.
Pro-inflammatory factors
Inflammation has been known to be a critical process in
the long-term progression of atherosclerosis for sometime [47,49,58]. C-reactive protein (CRP) is an acute phase
reactant that has been used as a marker of systemic in-
flammation in rheumatologic disorders. Retrospective and
prospective studies have found that high sensitivity CRP
(hsCRP) elevations are associated with acute CVD events
[59]. Ridker et al. found that men participating in the
Physicians’ Health Study who had hsCRP levels in the
highest quartile had a relative risk of 2.9 for MI and 1.9
for ischemic stroke compared to those in the lowest
quartile [59]. Furthermore, they found that aspirin was
associated with significant reductions in the risk of MI
in those with the highest hsCRP levels [59]. Ridker et al.
also found that hsCRP was a strong predictor of CVD
events in women participating in the Women’s Health
Study and that hsCRP may be a stronger predictor of
CVD events than LDL-C levels [60]. Furthermore, recent
meta-analyses have found that hsCRP is associated with risk
for CVD events and mortality [61,62]. There also appears
to be a relationship between hsCRP and LDL-C lowering.
In the PROVE IT Study, hsCRP lowering with statin ther-
apy was associated with reduced CVD events regardless of
the LDL-C lowering [63]. In the JUPITER Study, rosuvasta-
tin significantly decreased CVD events in patients with ele-
vated hsCRP (>2 mg/L) and ‘normal’ LDL-C (<130 mg/dL)
[64], suggesting the importance of hsCRP as a marker of
CVD risk and response to statin therapy. There is little
evidence, though, that lowering hsCRP levels prevents
CVD events [61]. In light of these findings, the new 2013
ACC/AHA Guideline on the Assessment of Cardiovascular
Risk recommends that, based on expert opinion, mea-
surement hsCRP may be considered as a marker of risk
to inform decision making on treatment options [5]. There
is evidence, though, to suggest that an anti-inflammatory
agent such as methotrexate is associated with reduced
CVD events in patients treated for rheumatoid arth-
ritis [65]. As such, there are currently trials designed
to examine whether anti-inflammatory agents reduce
CVD risk by reducing systemic inflammation, such as the
Cardiovascular Inflammation Reduction Trial sponsored
by the National Heart, Lung, and Blood Institute and
Brigham and Women’s Hospital investigating whether
low dose methotrexate reduces CVD outcomes in high
risk individuals, which may provide evidence for using
inflammatory markers as a treatment target.
Impaired glucose metabolism
Hyperglycemia and diabetes mellitus are clearly associated
with increased CVD risk [66-68]. There is evidence, though,
that mild hyperglycemia below the cutoffs for diabetes is
also associated with increased CVD risk [68]. Mild hyper-
glycemia or ‘pre-diabetes’ can manifest as either impaired
fasting glucose (IFG), impaired glucose tolerance (IGT),
and/or elevated hemoglobin A1c (HbA1c). These impair-
ments in glucose metabolism are associated with insulin
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high blood pressure, dyslipidemia, pro-inflammatory state
and pro-thrombotic state, all resulting in increased risk for
CVD [69]. It is more controversial whether hyperglycemia,
especially at mild, pre-diabetes levels, is a direct cause of
CVD. IFG using cutoffs of 110 mg/dl (6.0 mmol/l) [70] and
100 mg/dl (5.6 mmol/l) [71] has been shown to be inde-
pendently associated with increased CVD risk [72-74]. In a
recent meta-analysis, Ford et al. found that IFG was associ-
ated with an 18% to 20% increased risk in CVD [74]. Inter-
estingly, as has been shown in patients with ‘frank’ diabetes
[66], Levitzky et al. found that women with IFG had a close
to 1.7 to 2.2 fold increase in CHD while no effect was seen
in men [73]. Others, though, have not found a sex-based
difference in risk [74]. IGT has also been shown to be asso-
ciated with an increased risk of CVD [74-76]. It is less clear,
however, whether treating pre-diabetes improves CVD out-
comes. A number of diabetes prevention studies, including
the Diabetes Prevention Program, have been performed
in individuals with IGT but none have been powered to
examine CVD outcomes [77]. Thus, the modest risk of
CVD seen in those with pre-diabetes may be a result of
the associated comorbidities as opposed to a direct effect
of the mild hyperglycemia.
Subclinical ASCVD
Subclinical atherosclerosis is common and responsible
for first CVD events including major coronary artery oc-
clusion including sudden death in 40% to 60% of CHD
patients in the United States [78]. This section will ad-
dress only non-invasive techniques to assess this disease
burden. Ankle-brachial index (ABI) is a cheap, easily
employed method to asses for peripheral arterial disease
(PAD) and as a predictor of CVD events. The ABI is the
ankle systolic blood pressure divided by the brachial ar-
tery systolic blood pressure obtained while the patient is
supine with a value of ≤0.9 considered abnormal. Des-
pite its simplicity, the United States Preventive Services
Task Force has determined that ‘the current evidence is
insufficient to assess the balance of benefits and harms
of screening for PAD and CVD risk assessment with the
ABI in adults’ [79]. B-mode ultrasonography is most
often utilized to assess the thickness of the arterial
intimal and the medial layers (CIMT) in the common
carotid artery. However, the 2013 ACC/AHA Guideline
on the Assessment of Cardiovascular Risk Work Group
report judged that the evidence provided by Den Ruijter
et al. [80] in combination with the concerns about meas-
urement quality failed to provide sufficient rationale to
recommend measuring common carotid IMT in routine
clinical practice for CVD risk assessment for a first ath-
erosclerotic cardiovascular disease (ASCVD) event [5].
Moreover, the systematic review of van den Oord et al.
failed to demonstrate added value of carotid IMT totraditional risk models in predicting CVD events [81].
Important issues related to carotid IMT as an assess-
ment of ASCVD risk include measurement error and
standardization. The Den Ruijter et al. report was a
meta-analysis of 14 population-based cohorts with a
median follow-up of 11 years in 45,828 individuals with
4,007 MIs or strokes.
Electron-beam computed tomography (CT) measures
coronary artery calcification, a process related to the
lipid and apoptotic characteristics of the plaque. In
1,726, 57.7 +/- 13.3-year-old, asymptomatic individuals,
an Agatston score >75th percentile was associated with
a higher annualized event rate for myocardial infarc-
tion (3.6% versus 1.6%, P <0.05) and for cardiac death
(2.2% versus 0.9%) compared with patients with
scores <75th percentile [82]. Moreover, no cardiac events
were observed in patients with coronary calcium scores of
zero. In the Multi-Ethnic Study of Atherosclerosis (MESA),
6,814 subjects were examined over a mean follow-up
period of 7.6 years to determine the area under the re-
ceiver operator characteristic (ROC) curve (AUC) and
net reclassification improvement of coronary calcium
in comparison to a series of additional CVD risk fac-
tors when added to the Framingham Risk Score [83].
In MESA, the coronary artery calcium was superior to
other predictors of CHD/CVD, such as hsCRP, family
history and ankle-brachial index, in reclassifying risk
and discriminating the extent of CHD in intermediate-risk
subjects. This study is particularly important because the
improvement in ROC characteristics improved prediction
above and beyond current multivariate prediction models.
The 2013 ACC/AHA Guideline on the Assessment of
Cardiovascular Risk Work Group notes used the system-
atic review by Peters et al. [84]. to provide evidence that
assessing coronary artery calcification is likely to be the
most useful of the current approaches to improving risk
assessment among individuals found to be at intermedi-
ate risk after formal risk assessment [5]. Furthermore,
the Work Group noted that the outcomes in the studies
reviewed by Peters et al. [84]. and by Greenland et al.
[85] were CHD outcomes, not hard ASCVD events that
included stroke; thus, uncertainty remains regarding the
contribution of assessing coronary artery calcium to es-
timating 10-year risk of first hard ASCVD events after
formal risk assessment using the new Pooled Cohort
Equations. Furthermore, issues of cost and radiation ex-
posure related to measuring coronary calcium were dis-
cussed resulting in some uncertainty regarding potential
risks of more widespread screening; thus, a Class IIb
recommendation was given for individuals for whom a
risk-based treatment decision is uncertain after formal
risk estimation. Recent MESA data have provided add-
itional information that not only the volumetric score
but the density of the plaque need to be considered in
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analysis at any level of plaque volume, coronary artery
calcium density was inversely and significantly associ-
ated with CHD and CVD risk. This result suggests that
plaque remodeling by reduction in apo B-containing
lipoproteins and inflammation may serve to consoli-
date lesions and render them more stable.
By obtaining ECG-gated images, contrast-enhanced
multi-slice or multi-detector CT, also known as MDCT,
provides a more sensitive method than electron beam
CT to detail coronary anatomy. Moreover, diagnostic
performance of coronary CT angiography has been sub-
stantially improved with the technological developments in
multi-slice CT scanners which started with 4-slice and now
has advanced to 320-slice capability [87]. The exact place of
MDCT remains unclear but the elimination of unnecessary
high dose radiation exposure is an important consideration
[88]. Perhaps the best place for MDCT is as an alternative
to invasive coronary angiography in asymptomatic patients
who have a positive stress test [88].
High-resolution magnetic resonance imaging (MRI)
with contrast may be the most promising technique for
studying athero-thrombotic disease in humans [89]. Most
importantly, MRI allows for the characterization of plaque
composition including the lipid core, fibrosis, calcification,
intra-plaque hemorrhage and importantly thrombi, and not
only their presence but age, also. In asymptomatic subjects
with subclinical markers of CVD and in those with no co-
ronary calcium, coronary artery MRI has been used to de-
tect increased vessel wall thickness [90]. Although there are
limitations to its use including image resolution and imaging
time, coronary MRI opens new strategies for the screening
of higher risk patients for early detection and treatment as
well as monitoring of lesions after therapeutic intervention.
Conclusions
The purpose of this review was to update the science of
emerging cardiometabolic risk factors that were originally
discussed in the NCEP/ATPIII report of 2001 (updated in
2004). While there are more published data regarding the
evidence for using these risk factors there continues to
be significant debate and lack of consensus in their use
as illustrated in Table 1 which summarizes more current
recommendations (European, Canadian and American).
Thus, the use of these biomarkers for patients at interme-
diate risk of a major cardiovascular event remains prudent
in assisting in the identification of patients who need more
aggressive LDL-C or non-HDL-C lowering therapy.
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